A widely used arthritis medication for dogs may be associated with severe side effects, including seizures and muscle loss, according to a review by the US Food and Drug Administration (F.D.A.). The agency has recommended that the manufacturer update the drug’s label to reflect these potential risks.
Librela is an injection of monoclonal antibodies that blocks nerve growth factor, a protein involved in pain transmission. While it can provide significant benefits for mobility and quality of life in some dogs, veterinarians warn that there are risks involved, particularly for dogs with underlying neurological conditions.
The F.D.A.’s analysis of over 3,600 adverse-event reports found that the most common side effects were loss of muscle coordination and control, as well as muscle weakness, lameness, paralysis, and an inability to stand. Some owners have reported serious side effects, including death, shortly after administering the drug.
Zoetis, the manufacturer of Librela, maintains that side effects are rare, but acknowledges that the label may need to be revised. The company is working with the F.D.A. on this process.
Source: https://www.nytimes.com/2024/12/19/science/fda-drugs-dogs-arthritis-librela.html